AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$LQDA

Boyle Dana sold $168K of LQDA

Boyle Dana (Chief Accounting Officer) sold 5,892 shares of Liquidia Corp (LQDA) at $28.48 ($0.17M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boyle Dana
Published Oct 13, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate price impact.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings provide transparent disclosure of insider transactions.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Accounting Officer sold 5,892 shares for $167,804 via a 10b5-1 plan, reducing holdings to 165,609 shares.

Expected impact

likely modest pressure as the market prices in the insider sell.

Evidence & confidence

The sale is modest in size relative to the company's market cap and follows a pre‑arranged plan, so impact is limited.

Market effects

Sector

Minimal; insider sale does not affect the broader biotech sector.

Regional

None; the filing is company‑specific.

Global

Low; no macro or global implications.

Counterpoint

What could challenge this read

The sale could be routine and not indicative of any underlying weakness.

Key entities

  • Company
    Liquidia Corp

    Biopharmaceutical company listed on NASDAQ.

  • Insider
    Boyle Dana

    Chief Accounting Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min